Beta-lactam/ beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended spectrum beta-lactamase producing Enterobacteriaceae: Systematic review and meta-analysis
International journal of antimicrobial agents | 7 Aug 2018
M Sfeir, G Askin and P Christos
Infections due to extended-spectrum beta-lactamases (ESBL)-producing Enterobacteriaceae pose a major public health threat due to poor outcomes and high mortality rates. We aimed to conduct a systematic review and meta-analysis to investigate the impact of intravenous beta-lactam/ beta-lactamase inhibitors (BL-BLI) including piperacillin-tazobactam (PTZ) on mortality of patients with ESBL- producing Enterobacteriaceae bloodstream infections compared to carbapenem.
* Data courtesy of Altmetric.com